This is a news story, published by Yahoo Finance, that relates primarily to Zepbound news.
For more Zepbound news, you can click here:
more Zepbound newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
new Lilly drug Zepbound. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest FDA news, FDA label news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
pharma giantInsider
•84% Informative
Goldman Sachs says weight-loss drug market will be worth $130 billion by 2030 .
New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast.
Eli Lilly and Novo Nordisk will remain the dominant players with a combined market share of 80% .
VR Score
86
Informative language
86
Neutral language
50
Article tone
formal
Language
English
Language complexity
43
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
6
Source diversity
2
Affiliate links
no affiliate links